Federal lawmakers are concerned that a recent cyberattack on pharma giant Merck & Co. could lead to numerous problems. including a drug shortage.
U.S. Vice President Mike Pence urged fellow Republicans to get behind the party’s “last best chance” to repeal and replace Obamacare as congressional leaders scrambled to secure enough support ahead of a planned vote.
U.S. employers are bracing for higher health care expenses in 2018 as spending on new drugs to treat diseases such as cancer, multiple sclerosis and hepatitis C is expected to rise more than 7 percent, according to consultancy firm Mercer.
Structural improvements over the last decade to Houston hospitals have helped them to avoid devastation like Hurricane Katrina in New Orleans in 2005, but the pounding it received from Tropical Storm Harvey is expected to financially hobble many already strained Texas medical centers.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the International Society for Pharmacoepidemiology (ISPE) announced their plans for a one-day conference focused on real-world evidence.
Marketers need to dig deeper to facilitate communications that are dynamic enough to reach and engage patients on a more personal, emotional level.
U.S. Attorney General Jeff Sessions will unveil a major crackdown on healthcare fraud involving opioid treatment programs, Bloomberg News reported, citing two people familiar with the matter.
The white paper explores trends and market forces affecting organized provider groups (OPGs) and identifies opportunities for pharmaceutical manufacturers to partner with OPGs to develop mutually beneficial programs addressing areas of shared interest.
A bill passed by U.S. House Republicans would cause 23 million people to lose healthcare coverage by 2026 while de-stabilizing health insurance markets in some states and making it hard for sick people to buy insurance, a budget watchdog agency said.
It’s easy for politicians and consumers to rage about the high price of prescription drugs, but Wayne Winegarden, Pacific Research Institute’s senior fellow in business and economics, said those prices are not to blame for the high cost of healthcare in the United States.